220 related articles for article (PubMed ID: 28581672)
1. Preliminary investigations into developing all-D Omiganan for treating Mupirocin-resistant MRSA skin infections.
Ng SMS; Teo SW; Yong YE; Ng FM; Lau QY; Jureen R; Hill J; Chia CSB
Chem Biol Drug Des; 2017 Dec; 90(6):1155-1160. PubMed ID: 28581672
[TBL] [Abstract][Full Text] [Related]
2. Designing an ultra-short antibacterial peptide with potent activity against Mupirocin-resistant MRSA.
Arfan G; Ong CYF; Ng SMS; Lau QY; Ng FM; Ong EHQ; Hill J; Chia CSB
Chem Biol Drug Des; 2019 Jan; 93(1):4-11. PubMed ID: 30103288
[TBL] [Abstract][Full Text] [Related]
3. TXA497 as a topical antibacterial agent: comparative antistaphylococcal, skin deposition, and skin permeation studies with mupirocin.
Dorrani M; Kaul M; Parhi A; LaVoie EJ; Pilch DS; Michniak-Kohn B
Int J Pharm; 2014 Dec; 476(1-2):199-204. PubMed ID: 25263100
[TBL] [Abstract][Full Text] [Related]
4. New Synergistic Combination Therapy of Mupirocin and α-Pinene Against Multidrug-Resistant Clinical Strains of Methicillin-Resistant Staphylococcus aureus.
Cáceres-Guido P; Martín-Vázquez N; Ojeda-Sana A; Van Baren C; Balbarrey Z; Moreno S
P R Health Sci J; 2024 Jun; 43(2):73-78. PubMed ID: 38860960
[TBL] [Abstract][Full Text] [Related]
5. Designing a leucine-rich antibacterial nonapeptide with potent activity against mupirocin-resistant MRSA via a structure-activity relationship study.
Ang QA; Arfan G; Ong CYF; Ng FM; Ong EHQ; Chia CSB
Chem Biol Drug Des; 2021 Jun; 97(6):1185-1193. PubMed ID: 33754480
[TBL] [Abstract][Full Text] [Related]
6. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA.
Poovelikunnel T; Gethin G; Humphreys H
J Antimicrob Chemother; 2015 Oct; 70(10):2681-92. PubMed ID: 26142407
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of mupirocin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates by phenotypic and genotypic methods].
Us T; Kural M; Yayla B; Kiremitçi A; Cetin E; Akgün Y
Mikrobiyol Bul; 2009 Jul; 43(3):353-64. PubMed ID: 19795610
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse Model.
Mohammad H; Cushman M; Seleem MN
PLoS One; 2015; 10(11):e0142321. PubMed ID: 26536129
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of mupirocin resistance in Staphylococcus aureus.
Hetem DJ; Bonten MJ
J Hosp Infect; 2013 Dec; 85(4):249-56. PubMed ID: 24144552
[TBL] [Abstract][Full Text] [Related]
10. [Mupirocin resistance in methicillin-resistant Staphylococcus aureus strains isolated from wound infections].
Dolapçi I; Karahan ZC; Tekeli A; Koyuncu E; Azap A; Adaleti R
Mikrobiyol Bul; 2007 Jul; 41(3):435-40. PubMed ID: 17933255
[TBL] [Abstract][Full Text] [Related]
11. In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.
Narayanaswamy VP; Giatpaiboon SA; Uhrig J; Orwin P; Wiesmann W; Baker SM; Townsend SM
PLoS One; 2018; 13(1):e0191522. PubMed ID: 29342216
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of plasmid-mediated high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in four Spanish health care settings.
Pérez-Roth E; Potel-Alvarellos C; Espartero X; Constela-Caramés L; Méndez-Álvarez S; Alvarez-Fernández M
Int J Med Microbiol; 2013 May; 303(4):201-4. PubMed ID: 23611629
[TBL] [Abstract][Full Text] [Related]
13. Detection of methicillin-resistant Staphylococcus aureus with high-level resistance to mupirocin.
Nakajima J; Hitomi S; Kurihara Y
J Infect Chemother; 2011 Dec; 17(6):868-71. PubMed ID: 21484296
[TBL] [Abstract][Full Text] [Related]
14. NP108, an Antimicrobial Polymer with Activity against Methicillin- and Mupirocin-Resistant Staphylococcus aureus.
Mercer DK; Katvars LK; Hewitt F; Smith DW; Robertson J; O'Neil DA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607014
[No Abstract] [Full Text] [Related]
15. Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections.
Goldmann O; Cern A; Müsken M; Rohde M; Weiss W; Barenholz Y; Medina E
J Control Release; 2019 Dec; 316():292-301. PubMed ID: 31715276
[TBL] [Abstract][Full Text] [Related]
16. A novel membrane-disruptive antimicrobial peptide from frog skin secretion against cystic fibrosis isolates and evaluation of anti-MRSA effect using Galleria mellonella model.
Yuan Y; Zai Y; Xi X; Ma C; Wang L; Zhou M; Shaw C; Chen T
Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):849-856. PubMed ID: 30802593
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of high-level mupirocin resistance among meticillin-resistant Staphylococcus aureus isolates in a tertiary care hospital in Singapore.
Choudhury S; Krishnan PU; Ang B
J Hosp Infect; 2012 Sep; 82(1):56-7. PubMed ID: 22854355
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prevalence of low and high level mupirocin resistance in methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital.
Nizamuddin S; Irfan S; Zafar A
J Pak Med Assoc; 2011 Jun; 61(6):519-21. PubMed ID: 22204200
[TBL] [Abstract][Full Text] [Related]
19. Membrane-Active Amphipathic Peptide WRL3 with in Vitro Antibiofilm Capability and in Vivo Efficacy in Treating Methicillin-Resistant Staphylococcus aureus Burn Wound Infections.
Ma Z; Han J; Chang B; Gao L; Lu Z; Lu F; Zhao H; Zhang C; Bie X
ACS Infect Dis; 2017 Nov; 3(11):820-832. PubMed ID: 28885829
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of methicillin resistant Staphylococcus aureus (MRSA) isolates with high-level mupirocin resistance from patients and personnel in a burn center.
Abbasi-Montazeri E; Khosravi AD; Feizabadi MM; Goodarzi H; Khoramrooz SS; Mirzaii M; Kalantar E; Darban-Sarokhalil D
Burns; 2013 Jun; 39(4):650-4. PubMed ID: 23499497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
